Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
OtherArticle

Optimized pyridazinone nutrient channel inhibitors are potent and specific antimalarial leads

Michelle M Butler, Samanthi L. Waidyarachchi, Jinfeng Shao, Son T. Nguyen, Xiaoyuan Ding, Steven C. Cardinale, Lucas R. Morin, Steven M. Kwasny, Mai Ito, Jeanine Gezelle, Maria B. Jiminez-Di­az, Inigo Angulo-Barturen, Robert T. Jacobs, Jeremy N. Burrows, Zachary D. Aron, Terry L. Bowlin and Sanjay A. Desai
Molecular Pharmacology July 7, 2022, MOLPHARM-AR-2022-000549; DOI: https://doi.org/10.1124/molpharm.122.000549
Michelle M Butler
1Microbiotix, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mbutler@microbiotix.com
Samanthi L. Waidyarachchi
1Microbiotix, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinfeng Shao
2Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Son T. Nguyen
1Microbiotix, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoyuan Ding
1Microbiotix, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven C. Cardinale
1Microbiotix, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucas R. Morin
1Microbiotix, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven M. Kwasny
1Microbiotix, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mai Ito
2Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeanine Gezelle
2Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria B. Jiminez-Di­az
3The Art of Discovery SL, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inigo Angulo-Barturen
3The Art of Discovery SL, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert T. Jacobs
4Medicines for Malaria Venture, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy N. Burrows
4Medicines for Malaria Venture, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zachary D. Aron
1Microbiotix, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terry L. Bowlin
1Microbiotix, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay A. Desai
5LMVR/NIAID, National Institutes of Health, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Additional Files

  • Data Supplement

    • Supplemental Data -

      Supplemental Scheme 1: Synthesis of pyridazinone compounds. Reagents and conditions: (a) N2H4.H2O, EtOH, reflux, 7 h, 61 %. (b) 3-Nitrobenzenesulfonate, NaOH, H2O, 100 °C, 2 h (c) HSO3Cl, PCl5, CHCl3, 0 °C to RT, 5h, 33.8 %. (d) DIPEA, DMF, 3 h, RT, 70%.

      Supplemental Table 1. In vitro Safety Panel and CYP profiling results for MBX-4055.

      Supplemental Table 2. Pharmacokinetic parameters for compounds MBX-2366, MBX-3318, MBX-3477A and 3976.

      Supplemental Table 3. Murine tolerability for compounds MBX-2366, 3318, 3477A, 3976 and 4055.

      Supplemental Figure 1. Murine pharmacokinetics

Next
Back to top

In this issue

Molecular Pharmacology: 102 (3)
Molecular Pharmacology
Vol. 102, Issue 3
1 Sep 2022
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Optimized pyridazinone nutrient channel inhibitors are potent and specific antimalarial leads
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherArticle

Pyridazinone antimalarial leads

Michelle M Butler, Samanthi L. Waidyarachchi, Jinfeng Shao, Son T. Nguyen, Xiaoyuan Ding, Steven C. Cardinale, Lucas R. Morin, Steven M. Kwasny, Mai Ito, Jeanine Gezelle, Maria B. Jiminez-Di­az, Inigo Angulo-Barturen, Robert T. Jacobs, Jeremy N. Burrows, Zachary D. Aron, Terry L. Bowlin and Sanjay A. Desai
Molecular Pharmacology July 7, 2022, MOLPHARM-AR-2022-000549; DOI: https://doi.org/10.1124/molpharm.122.000549

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherArticle

Pyridazinone antimalarial leads

Michelle M Butler, Samanthi L. Waidyarachchi, Jinfeng Shao, Son T. Nguyen, Xiaoyuan Ding, Steven C. Cardinale, Lucas R. Morin, Steven M. Kwasny, Mai Ito, Jeanine Gezelle, Maria B. Jiminez-Di­az, Inigo Angulo-Barturen, Robert T. Jacobs, Jeremy N. Burrows, Zachary D. Aron, Terry L. Bowlin and Sanjay A. Desai
Molecular Pharmacology July 7, 2022, MOLPHARM-AR-2022-000549; DOI: https://doi.org/10.1124/molpharm.122.000549
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The Regulation and Mechanisms of ImKTX58 on KV1.3 Channel
  • Human mAb 3F1 Targeting the Functional Epitopes of Siglec-15
  • Effects of Small Molecule Ligands on ACKR3 Receptors
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics